Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01660191 · ClinicalTrials.gov registry record · Phase 4

A Study Comparing CoQ10 Levels While Taking 3 Different Statins

A Phase 4 study of Hypercholesterolemia, sponsored by University of Kansas Medical Center.

Completed
Registry status
Phase 4
Development phase
134
Enrollment target
1
Study location

NCT01660191 is a Phase 4 study of Hypercholesterolemia that has completed, run by University of Kansas Medical Center. The registered enrollment target is 134 participants, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01660191, a Phase 4 study of Hypercholesterolemia, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
134 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.

Conditions Studied

Interventions

  • DRUG Atorvastatin 20mg
  • DRUG Pitavastin 4mg
  • DRUG Rosuvastatin 5mg

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2011-12
Est. Completion 2013-10
Phase Phase 4

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT01660191

The ClinicalTrials.gov registry entry for NCT01660191 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (84% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 3 interventions - of which Atorvastatin 20mg is the first listed.

NCT01660191 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT01660191 about?

NCT01660191 is a clinical study titled "A Study Comparing CoQ10 Levels While Taking 3 Different Statins". The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.

What is the current status of trial NCT01660191?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2011-12. Estimated completion is 2013-10.

What conditions does trial NCT01660191 study?

This clinical trial studies the following conditions: Hypercholesterolemia.

What interventions are being tested in trial NCT01660191?

The interventions under investigation include: Atorvastatin 20mg (DRUG), Pitavastin 4mg (DRUG), Rosuvastatin 5mg (DRUG).

Who is sponsoring clinical trial NCT01660191?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01660191 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.